InVitae (NVTA) Misses Q1 EPS by 1c, Revenues Beat

InVitae (NYSE: NVTA) reported Q1 EPS of ($0.80), $0.01 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $64.25 million versus the consensus estimate of $59.41 million.

"We started the year with a very strong quarter, delivering record growth in volume and first quarter revenues and giving us strong momentum as we began experiencing impacts from the pandemic. As healthcare has shifted, we have been able to quickly leverage our pre-existing strengths, notably our telehealth offerings and our ability to deliver genetic testing remotely," said Sean George, co-founder and chief executive officer of Invitae. \"Looking ahead, our investments in diversified products, services, technologies and geographies mean we are well-equipped to drive growth across an increasing number of customer segments as we drive genetics into mainstream medicine."

For earnings history and earnings-related data on InVitae (NVTA) click here.

You May Also Be Interested In

• Top AI Semiconductor Stocks According to Stifel Analysis
• TD Cowen on Pepsico (PEP): 'Ongoing Weakness in North America Drives Guidance Cut'
• Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance